RAGE Signaling Significantly Impacts Tumorigenesis and Hepatic Tumor Growth in Murine Models of Colorectal Carcinoma

Journal of Gastrointestinal Surgery

Volumn 14, Issue 11, 2010, Pages 1680-1690

  DiNorcia, Joseph ^a   Moroziewicz, Dorota N ^a   Ippagunta, Nikalesh ^a   Lee, Minna K ^a   Foster, Mark ^a   Rotterdam, Heidrun Z ^a   Bao, Fei ^a   Zhou, Yu Shan ^a   Yan, Shi Fang ^a   Emond, Jean ^a   Schmidt, Ann Marie ^a   Allendorf, John D ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b NONE   (United States)

Author keywords

Colon cancer; Colorectal carcinoma; RAGE; Rage knockout mice; Receptor for advanced glycation end products; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; LIVER TUMOR; METASTASIS; MOUSE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; GLYCOSYLATION END PRODUCTS, ADVANCED; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77958504419     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1347-z     Document Type: Article

References (32)

1. Jemal A, Siegel R., Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA cancer J Clin 2009; 59: 225-249.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
3. McCart AE, Vickaryous NK, Silver A. Apc mice: Models, modifiers and mutants. Pathol Res Pract 2008: 204; 479-490.
4. Vakkila J, Lotze MT. Inflammation and necrosis promote tumor growth. Nat Rev Immunol 2004; 4: 641-648.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
6. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-107.
7. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
8. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
9. Riehl A, Németh J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Comm Sig 2007; 7: 12.
10. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010; 31: 334-341.
11. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009; 86: 505-512.
12. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, Huang EH. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007; 50: 1230-1240.
13. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hor O, Ogawa S, Stern DM, Schmidt AM. Blockade of amphoterin/RAGE signaling suppresses tumor growth and metastases. Nature 2001; 405: 354-360.
14. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
15. Volp KL, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, Joos S, Zorniq M. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon adenocarcinoma. Gut 2006; 55: 234-242.
16. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005; 446: 411-415.
17. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-727.
18. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 445-448.
19. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005; 166: 751-759.
20. Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
21. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
22. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
23. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Investig 1995; 96: 1395-1403.
24. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Muller M, Nawroth PP. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-2271.
25. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus. A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy. Am J Pathol 2003; 162: 1123-1137.
26. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.
27. -/- mice. J Clin Invest 2008; 118: 183-194.
28. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, Kucherlapati R. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994; 91: 8969-8973.
29. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 1998; 4: 1025-1031.
30. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243.
31. Liang X, Romo de Vivar Chavez A, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, Zeh HJ, Beer-Stolz D, Lotze MT, de Vera ME. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 2009; 86: 599-607.
32. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010; 337: 251-258.